FINWIRES · TerminalLIVE
FINWIRES

生質燃料最新動態:大豆油可望連續第四個月上漲,棕櫚油價格回落

By

-- 週四,芝加哥大豆油期貨預計將連續第四個月上漲,而馬來西亞棕櫚油因出口放緩,部分回吐了上月漲幅。 芝加哥期貨交易所(CBOT)5月大豆油合約早盤走勢平穩,接近合約高點,每磅75.32美分。該合約本月可望上漲9.4%,與原油市場的強勁表現相符。 大豆油市場的強勁表現提振了大豆價格,CBOT 5月大豆合約週四有望實現0.7%的月度漲幅。早盤交易中,該合約較前一交易日收盤價下跌0.23%,至每蒲式耳11.79美元。 生物燃料需求的增長以及阿根廷大豆因降雨而延遲收割,支撐了大豆價格,並緩解了市場對供應過剩的擔憂。 根據Trading Economics的數據顯示,阿根廷棕櫚油目前的收成進度僅10%,而往年同期平均進度為60%。 巴西的棕櫚油收成已完成90%以上。據價格報告機構MySteel引述產業數據稱,4月巴西棕櫚油出口量可能年增21.5%,達到1,640萬噸。 在美國,棕櫚油種植速度仍高於五年平均水平,但部分地區的降雨可能會減緩種植進度。 在亞洲,馬來西亞棕櫚油期貨在交易日尾盤回落,月跌幅約6%,因為出口疲軟抵消了原油價格上漲和生物燃料需求成長帶來的利多。 馬來西亞衍生性商品交易所5月原棕櫚油合約下跌0.02%,結算價為每噸4,504馬來西亞林吉特(1,133.94美元)。 6月合約價格小幅下跌0.11%,至每噸4,540令吉。 4月的下跌部分抵消了上月因美伊衝突爆發而取得的19%的漲幅。 儘管原油價格走強,但MySteel表示,“(棕櫚油)市場可能會重新關注現貨市場的短期壓力。” 基本面疲軟繼續對價格構成壓力,尤其是根據貨運調查員估計,4月1日至25日期間馬來西亞棕櫚油出貨量較上月下降15.7%至16.8%。 季節性低迷過後,市場預期未來幾個月產量將有所回升,也加劇了市場悲觀情緒。 同時,由於擔心化肥成本飆升和可能發生的乾旱,全年產量展望顯示供應將趨緊。 根據路透社報道,印尼棕櫚油協會主席埃迪·馬托諾警告稱,如果厄爾尼諾現象持續發展,且農民在季末推遲施肥,該國棕櫚油產量可能下降100萬至200萬噸。 MySteel表示,“短期內,棕櫚油價格預計將在一定範圍內波動”,並指出高企的原油價格對棕櫚油價格的支撐有限。 在美國,紐約商品交易所(NYMEX)5月交割的乙醇期貨價格週三上漲3.27%,至每加侖2.05美元,因為產業數據顯示,每週出口量激增,產量下降。 美國能源資訊署的數據顯示,截至4月24日當週,乙醇出口量幾乎翻了一番,達到每日17萬桶,而前一周為每日9.1萬桶。但與去年同期的每日14.1萬桶相比,出口量也有所下降。 美國國內乙醇產量較上月下降至每日101萬桶,低於一週前和去年同期的每日104萬桶。 因此,美國乙醇庫存從前一周的2,690萬桶降至2,590萬桶。不過,這一水準仍高於去年同期的2,540萬桶。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.

$FE
Sectors

Sector Update: Consumer

Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.

$LW
Australia

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN